NASH is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and obesity have made liver disease a major public health challenge in China, where the prevalence of NASH is the highest. Owing to high unmet need and the lack of approved disease-modifying therapies (DMTs) in China, NASH is a market of lucrative potential for drug developers. Currently, only off-label, generic drugs are prescribed for NASH; however, we anticipate the launch and gradual but substantial uptake of branded DMTs, such as Galmed Pharmaceuticals’ Aramchol and Intercept Pharmaceuticals’ Ocaliva. These novel therapies will command premium pricing owing to the lack of pharmaco-therapeutic alternatives, driving tremendous growth of China’s NASH market throughout the forecast period. Additionally, multinational companies are likely to be increasingly incentivized to enter the NASH market in China with ongoing improvements to the market access and reimbursement environments in China, notably for diseases with a high unmet need.
- How large is China’s drug-treatable NASH population and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s NASH market and why? What are interviewed experts’ insights on current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the NASH pipeline in China? What sales / uptake could they secure in NASH? What are interviewed experts’ opinions on the key emerging therapies?
- What are the key drivers and constraints in the China NASH market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.
Qualitative and quantitative insights based on five country-specific interviews with thought-leading medical hepatologists and gastroenterologists and supported by survey data collected for this and other DRG research.
Diagnosed prevalence of NASH by disease stage. Clinically and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key NASH therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 0 drugs; Phase II: 4 drugs; coverage of select early-phase products.